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Abstract 
Early onset familial Paget’s disease of bone (EoPDB), familial expansile osteolysis and 
expansile skeletal hyperphosphatasia are related disorders caused by insertion mutations in 
exon 1 of the TNFRSF11A gene which encodes receptor activator of nuclear factor kappa B 
(RANK) protein. To understand the mechanisms underlying these disorders, we developed a 
mouse model carrying the 75dup27 mutation which causes EoPDB.  
Mice heterozygous for the mutation (Tnfrsf11a75dup27/-) developed a PDB-like disorder with 
focal osteolytic lesions in the hind limbs with increasing age. Treatment of these mice with 
zoledronic acid completely prevented the development of lesions. Studies in vitro showed that 
RANKL-induced osteoclast formation and signaling was impaired in bone marrow cells from 
Tnfrsf11a75dup27/-  animals, but that osteoclast survival was increased independent of RANKL 
stimulation.  Surprisingly, Tnfrsf11a75dup27/75dup27  homozygotes had osteopetrosis at birth, with 
complete absence of osteoclasts. Bone marrow cells from these mice failed to form osteoclasts 
in response to RANKL and M-CSF stimulation. This intriguing study has shown that in 
heterozygous form, the 75dup27 mutation causes focal osteolytic lesions in vivo reminiscent 
of the human disorder and extends osteoclast survival independently of RANKL signaling. In 
homozygous form however, the mutation causes osteopetrosis due to failure of osteoclast 
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Introduction 
Early onset Paget’s disease of bone (EoPDB) is a rare condition which has phenotypic overlap 
with both classical PDB and familial expansile osteolysis (1-3). It is caused by a heterozygous 
27-bp duplication in the signal peptide of TNFRSF11A gene (75dup27), leading to insertion of 
nine amino acids in the RANK signal peptide. It belongs to a group of related focal osteolytic 
disorders with distinct but overlapping features in which various insertion mutations occur in 
exon 1 of TNFRSF11A causing duplications of between five and nine amino acids in the RANK 
signal peptide (reviewed in (4)). Previous in vitro studies have shown that the causal mutations 
prevent cleavage of the RANK signal peptide, causing the mutant RANK molecules to 
accumulate in the Golgi apparatus, impairing its ability to translocate to the cell surface (3,5,6). 
This, in turn, has been shown to lead to defective RANKL signaling indicating that these are 
loss-of-function mutations that impair RANKL induced osteoclastogenesis (5,7). There remains 
a conundrum of exactly how loss of function mutations in TNFRSF11A can cause an osteolytic 
disorder in vivo. In order to investigate this, we generated a mouse model of the 75dup27 
insertion, confirming that this is a loss-of function mutation for RANKL-induced 
osteoclastogenesis in homozygous form, but is a gain of function mutation in heterozygous due 
to non-classical activation of NF-κB signaling.   
 
Materials and Methods 
Generation of the Tnfrsf11a75dup27/75dup27 mouse model  
Mice with the 75dup27 mutation were generated by gene targeting in embryonic stem cells 
according to classical techniques. The targeting construct was created by generating a 4.7 kb 
fragment by PCR from genomic DNA encompassing exon 1 of the mouse Tnfrsf11a gene and 
surrounding sequences. The 27bp insertion mutation was inserted in the first exon (Suppl 
Figure S1) by site-directed mutagenesis (Stratagene), followed by cloning a floxed neomycin 
cassette as a positive selection marker, a 2-kb 3’ homology region, and diphtheria toxin A 
(DTA) cassette as a negative selection marker. Supplementary figure S2A shows schematic 
representation of the targeting construct. The targeting construct was electroporated into 
129/Ola embryonic stem cells (ES). Following selection by culturing the ES cells in neomycin, 
three positive clones were identified, and fidelity of the targeting event was confirmed by 
southern blotting with probes at the 5’ and 3’ ends (Suppl. Fig. S2B). Targeted ES cells were 
injected into C57BL/6 blastocysts to generate chimeric animals.  The neomycin cassette was 
excised by crossing male chimeras with a CMV-Cre recombinase expressing C57BL/6 female. 
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Presence of the 27bp-insertion mutation was confirmed by DNA sequencing (Suppl. Figure 
S2C). The resulting C57BL/6-129Ola mixed-background animals were backcrossed into 
C57BL/6 for 10 generations and complete backcross was confirmed using Illumina mouse 
medium-density linkage panel following the manufacturer’s recommended protocol (Illumina 
Inc, USA). All mice were housed in a standard animal facility with free access to food (pelleted 
RM1; SDS diets, UK) and water. All experiments on mice were performed according to 
institutional and UK regulations.  
 Osteoclast cultures  
Bone marrow was flushed from long bones of 3-4-month-old mice of each genotype and 
cultured in α-MEM supplemented with 10% fetal calf serum, penicillin/streptomycin, 
glutamine and MCSF (100 ng/mL) for 48 hours. The culture medium containing non-adherent 
cells was removed and adherent cells, containing MCSF-dependent osteoclast precursors were 
removed by trypsinization and plated at a density of 104 cells/well in 96-well plates with 150 
µl of culture medium and MCSF at a concentration of 25 ng/mL and different concentrations 
of RANKL until osteoclasts were formed (4-5 days). At the end of the culture period the 
medium was removed and the cells were fixed with 4% formaldehyde in PBS and stained for 
TRAcP (8). Osteoclasts, defined as TRAcP+ cells with 3 or more nuclei, were counted using a 
10x-objective lens on a bright field microscope. Osteoclasts carrying more than 5 nuclei were 
counted separately. 
Osteoclast survival  
Osteoclasts were generated from bone marrow cells as described above and after 4-5 days in 
culture RANKL was withdrawn and cultures continued for periods of up to 42 hours. The 
cultures were stopped at the indicated time points and cells were fixed in 4% formaldehyde in 
PBS. Staining for osteoclasts was performed as described above.  
Western blot 
The cells were washed in 1 ml of ice-cold PBS and lysed in radioimmunoprecipitation assay 
(RIPA) buffer. Protein quantification was performed using the Pierce BCA protein assay kit 
(Life Technologies). Protein lysates were mixed with the appropriate volume of 5X sample 
loading protein buffer (10% SDS, 500mM DTT, 50% Glycerol, 250mM Tris-HCL and 0.5% 
bromophenol blue dye, PH 6.8) and  denatured at 95⸰ C on a dry bath for 3-5 min and 60-70 
µg loaded into pre-cast acrylamide gels (Bio Rad). Band separation was performed by 
electrophoresis at 200V for 35-45 min and proteins were transferred to a nylon membrane at 
60 mA for 2-3 h. c-Fos, ERK 1/2 (Thr202/Tyr204 p44/p42 MAPK), Ser32 IκB-α, 
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Thr180/Tyr182 p38 MAPK, as well as their phosphorylated counterparts were detected using 
rabbit polyclonal antibodies (Suppl Table S1). β-Actin or HPRT was used for normalization 
and detected using rabbit polyclonal antibody (Suppl Table S1). Horseradish peroxidase-
conjugated anti-rabbit secondary antibodies were used to visualize results using Supersignal 
chemiluminescence kit from Life Technologies in a Syngene Genegnome bioimaging system 
(Fisher Scientific). Intensities of bands were quantified using Image Studio Lite Ver 3.1 
software. 
NF-κB luciferase reporter assay 
MCSF-dependent macrophages were generated from mice as described above and seeded at a 
density of 1 x 106 cells and cultured in complete α-MEM medium for 24 hours. Subsequently, 
the cells were transduced with a lentiviral NF-kB luciferase reporter (NF-κB Cignal lenti 
luciferase reporter assay from SA Bioscience) at a multiplicity of infection (MOI) of 3 in 3ml 
serum free αMEM media for 5 hrs. An additional 3ml of standard α-MEM was then added to 
each flask and the cultures were incubated for two days followed by selection for another 48hrs 
using Puromycin (5µg/ml). The cells were then harvested, plated at 104 cells/well in 96 well 
plate and cultured in complete α-MEM for 24hrs. Luciferase activity was measured with a 
SteadyGlo-luciferase reporter assay system (Promega) at the indicated time points following 
RANKL stimulation (100ng/ml) until osteoclasts were formed, as well as 24 and 48 hrs. post 
RANKL withdrawal using a Bio-Tek Synergy HT plate reader. 
Measurement of biochemical markers 
Serum levels of P1NP, CTX-I (Immunodiagnostic Systems, UK) and RANKL (ThermoFisher 
Scientific, UK) were measures using enzyme-linked immunosorbent assay by following the 
manufacturer’s protocol.  
Bone micro-computed tomography (Micro CT) analysis 
MicroCT analysis was performed using a Skyscan 1172 system (Bruker, Belgium). The hind 
limbs of animals were dissected free of soft tissue, fixed in 4% formaldehyde in PBS, and 
tibial metaphysis and diaphysis were scanned ex vivo at a resolution of 5 µm (60 kV, 167 µA, 
using a 0.5 mm aluminum filter and a rotation step size of 0.3°). Image reconstruction was 
performed using the Skyscan NRecon package and trabecular and cortical bone parameters 
were measured using Skyscan CTAn software as described previously (9). Briefly, trabecular 
bone parameters were measured in a stack of 200 slices immediately distal from the growth 
plate and, for cortical bone parameters, in 100 slices at the mid shaft of the femur. 
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Semiquantitative analysis of osteolytic lesions 
The presence and numbers of osteolytic lesions were assessed on MicroCT images of the hind 
limbs. Bone lesions were analyzed using a semi-quantitative 3-point scoring system to grade 
the lesions based on the size and number of lesions observed. Each animal was given a total 
lesion score based on the sum of scores generated from the left and right hind limbs.  
Bone histology and histomorphometry 
Histological analysis was performed as described previously (12). After dissection, hind limbs 
were fixed for 24 h in 4% buffered formalin and stored in 70% ethanol. The samples were 
embedded in methyl methacrylate and sections were cut using a tungsten steel knife. Bone 
sections were stained for TRAcP to visualize osteoclasts and counterstained with Aniline 
Blue. Cartilage matrix was visualized using Safranin O staining and Fast green as a 
counterstain. To achieve imaging of entire sections, image fields were stitched together using 
Microsoft Ice software. Histomorphometry was performed using custom software based on 
Image J (10) and followed standardized nomenclature and recommendations (11).  
Bisphosphonate therapy 
Heterozygous Tnfrsf11a75dup27/- female mice were treated with zoledronic acid at a dose of 85 
µg/kg (n = 8) or vehicle (PBS; n=8) between 4 months and 12 months of age by subcutaneous 
injection every 2 months.  The experiment was terminated by culling the mice at 15 months of 
age, the limbs recovered and analyzed for the presence of bone lesions by microCT and 
histological analysis. 
Statistical analysis 
Differences between groups were assessed by unpaired Student’s T-test using SPSS for 
Windows version 19. A p-value < 0.05 was considered statistically significant. Data are 
presented as box and whiskers plots showing all data points, the interquartile range, the 
minimum and maximum values.  
 
Ethical considerations 
Ethical approval for the experiments was obtained from the Animal Welfare and the Ethical 
Review Body of the University of Edinburgh and the experiments were conducted according 
to the UK Animals Act of 1986 (Scientific Procedures).   
 
Results 
Phenotype of homozygous Tnfrsf11a75dup27/75dup27 mice  
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Mice that were homozygous for the 27-bp insertion of RANK (Tnfrsf11a75dup27/75dup27) were 
viable but were smaller than their wild type littermates. By the time of weaning, 
Tnfrsf11a75dup27/75dup27 mice lacked incisors, and they were fed a soft food diet.  They also had 
reduced survival; 31% (5 out of 16) of Tnfrsf11a75dup27/75dup27 mice died by 4 weeks of age 
compared to 0 % (0 out of 16) of wild type (WT) littermates. All Tnfrsf11a75dup27/75dup27 mice 
became progressively unwell with age due to the severe osteopetrosis phenotype and they had 
to be culled by the age of 4 months. None of the Tnfrsf11a75dup27/75dup27 mice had incisors by 
the time of culling. Radiographic analysis of these mice showed metaphyseal widening and 
sclerosis of the tibia and femur characteristic of osteopetrosis (Figure 1). The osteopetrosis was 
confirmed by MicroCT which also showed metaphyseal widening and thinning of the cortex 
(Figure 2). This phenotype was fully penetrant and affected all 16 mice analyzed. Detailed 
MicroCT analysis showed that Tnfrsf11a75dup27/75dup27 mice had significantly higher BV/TV, 
trabecular number and trabecular thickness compared to WT whereas the trabecular separation 
was significantly lower than WT. (Figure 2). The trabecular area and peripheral circumference 
of tibiae were also significantly higher in homozygous mice.  Histological analysis of Safranin-
O and Fast Green stained sections showed expansion of the growth plate and the bone marrow 
cavity was filled with mineralized cartilage. No osteoclasts were detected upon TRAcP staining 
of bone sections from homozygous animals (Figure 2). In keeping with these observations, 
bone marrow-derived macrophages from Tnfrsf11a75dup27/75dup27 mice failed to form osteoclasts 
in vitro in response to RANKL and M-CSF (Figure 2H).  
 
Phenotype of heterozygous Tnfrsf11a75dup27/- mice.  
Heterozygous Tnfrsf11a75dup27/- mice were viable and fertile, had normal survival and had a 
body size similar to wild type littermates. Analysis by X-ray showed no major differences 
between heterozygous and WT but some animals (3 out of 18) aged between 12-15 months 
showed osteolytic lesions in the tibia (Figure 1). MicroCT analysis of female 4-month old 
mice showed normal trabecular bone density and structure (Supplementary Table S2) with no 
evidence of osteolytic bone lesions. Consistent with the MicroCT results, histomorphometry 
of 4 month-old animals also showed no differences in bone density between WT and 
Tnfrsf11a75dup27/-  animals (Supplementary Table S3). There was a trend for reduced Oc.S/BS 
and Oc.N/BS in heterozygous animals compared to WT but this was not statistically 
significant. Analysis of 4-month old male mice revealed similar results to those from female 
mice (data not shown). 
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We went on to analyze bone density and architecture by microCT of 12- and 15-month-old 
mice. We found that trabecular bone volume/tissue volume (BV/TV), trabecular thickness 
(Tb.Th), and trabecular number (Tb.N) were significantly higher in 12-month old 
Tnfrsf11a75dup27/- mice compared to WT (Figure 3). Additionally, trabecular separation 
(Tb.Sp) was significantly lower in Tnfrsf11a75dup27/- mice compared to WT. There was a trend 
for larger cortical thickens (Cort.Th) in Tnfrsf11a75dup27/- mice but this was not statistically 
significant (Figure 3). We observed larger peripheral circumference in Tnfrsf11a75dup27/- mice 
compared to WT indicating bone enlargement (Figure 3B).  However, analysis of the skull 
bone showed no significant differences in morphology, width, length or height between Het 
and WT mice (Figure 3C and D). 
We then assessed the mice for the presence of bone lesions by analysis of MicroCT images of 
the hind limbs. Results from 12-month-old mice showed lytic lesions at the proximal tibia 
and distal femur close to the growth plate and at both lower femoral condyles in 
Tnfrsf11a75dup27/- mice (Figure 4A). These lesions were similar to those previously reported in 
other mouse models of Paget’s disease (12-14). Most 12-month old heterozygous animals (7 out 
of 8) showed lesions similar to those shown in Figure 4A but by 15 months all (10 out of 10) 
Tnfrsf11a75dup27/- mice had developed lesions. However, some animals showed lesions in one 
limb only (2 out of 8 by 12 months and 2 out of 10 by 15-months) reminiscent of the focal 
nature of PDB. Analysis of bone lesion severity score showed a significantly higher score in 
heterozygous animals compared to WT (Figure 4B). The severity score was found to increase 
with age as 15-month-old animals had significantly higher score than 12-month-old animals 
(P=0.005). 
A small number of heterozygous animals (3 out of 18) developed larger focal lesions in the 
tibial shaft of one limb as shown in Figure 4E and F. Histological analysis of these lesions 
revealed disorganized bone structure with a large number of osteoclasts in the area affected 
by the lesion (74.5 ± 7.8 OC/mm2) compared to the WT (5.9 ± 4.8; P= 4 x 10-7; Figure 4E-F). 
Similarly, osteoblast numbers were higher in the lesion area (147.1 ± 8.8 OB/mm2) compared 
to WT (21.6 ± 3.9; P=5 x 10-9).   
 
Osteoclasts cultured from bone marrow cells of heterozygous Tnfrsf11a75dup27/- mice were 
fewer in number and had a smaller number of nuclei than those formed from wild type 
littermates (Figure 5A-B). They also appear to have a denser TRAcP staining compared to the 
WT osteoclasts.  The percentage of larger osteoclasts (more than 5 nuclei) was decreased in 
cultures from Tnfrsf11a75dup27/- mice compared to wild type at both 100 and 200 ng/mL (Figure 
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5C). Analysis of osteoclast survival following withdrawal of RANKL showed that the 
percentage of surviving osteoclasts was significantly higher in the Tnfrsf11a75dup27/- cultures 
compared to wild type at all time points analyzed (Figure 5D).  
 
Effect of Tnfrsf11a75dup27/- mutation on NF-kB signaling in vitro 
In order to investigate the signaling mechanisms underlying the in vitro results for the 
Tnfrsf11a75dup27/-  model, we analyzed ERK, IκB and p38 MAPK, c-Fos, and NF-κB pathways 
in MCSF-dependent macrophages in response to RANKL. We found no difference in ERK 
phosphorylation at baseline but following RANKL stimulation, there was an increased 
phosphorylation of ERK in osteoclasts cultured from Tnfrsf11a75dup27/- mice compared to WT 
and by 30 minutes, the levels of pERK in Tnfrsf11a75dup27/- mice were significantly higher than 
WT (Figure 6). However, IκB phosphorylation was significantly reduced in Tnfrsf11a75dup27/- 
osteoclasts after 10-15 min stimulation with RANKL compared with WT. Levels of 
phosphorylated p38 were greatly reduced in osteoclasts cultured from Tnfrsf11a75dup27/-  mice 
compared to wild type, such that the mutant osteoclasts showed attenuated responses to 
RANKL. Analysis of c-Fos showed a significant increase in its level in mutant osteoclast 
precursor cells compared to WT but after RANKL stimulation, c-Fos levels were comparable 
to WT (Fig 6C).  To assess NF-κB activity during osteoclast differentiation, we used a NF-κB 
luciferase reporter assay and found decreased NF-κB activity in the Tnfrsf11a75dup27/- at all 
stages during osteoclast differentiation compared with WT (Figure 6 E). However, when 
RANKL was withdrawn, NF-κB activity was higher in Tnfrsf11a75dup27/- cells, compared with 
wild type (Figure 6F).  
We then assessed the effect of Tnfrsf11a75dup27/- mutation on serum levels of RANKL and 
biochemical markers of bone turnover in 4-month-old mice. We found no difference in serum 
levels of P1NP or CTX-I between Tnfrsf11a75dup27/- and WT but serum levels of RANKL 
were significantly lower in the mutant mice compared to WT (Figure 7). 
 
Zoledronic acid prevents development of osteolytic lesions in heterozygous Tnfrsf11a75dup27/- 
mice 
Administration of zoledronic acid between 4 and 12 months of age completely prevented the 
development of osteolytic lesions in heterozygous Tnfrsf11a75dup27/- mice whereas multiple 
lesions developed in the group receiving vehicle to a similar extent as in untreated heterozygous 
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mice (Figure 8). No obvious adverse effects were detected in mice which received zoledronic 
acid or PBS.   
 
Discussion 
Early onset Paget’s disease of bone is a rare condition caused by a heterozygote duplication of 
9 amino acids in the signal peptide of the RANK protein due a 27bp duplication in exon 1 of 
TNFRSF11A. It shares some of the clinical features of classical PDB, but has an earlier age of 
onset, and is characterized by early onset deafness, premature tooth loss, and prominent 
involvement of the mandible and maxilla (1). Early functional studies of the TNFRSF11A 27bp 
duplication showed that when constructs containing the mutant allele were over-expressed in 
HEK293 cells, there was an evidence of increased constitutive NF-κB activation in promoter-
reporter assays when compared with wild type (3). These observations were confirmed by 
Crockett and colleagues but when the 75dup27 allele and the related 84dup18 and 84dup15 
alleles were stably expressed as a single copy in HEK 293 cells, there was no evidence of 
increased NF-κB activation. Furthermore, Crockett et al (5) demonstrated that cells stably 
expressing these three mutant alleles failed to respond to RANKL stimulation and that the 
mutant proteins failed to translocate to the cell surface, but instead accumulated in organized 
smooth endoplasmic reticulum (OSER) - like structures. The overall conclusion from 
Crockett’s experiments were that the insertion mutations were loss-of-function variants that 
result in a failure to respond to RANKL in vitro.  
The experiments described here confirm that the 75dup27 mutation is a loss-of function variant 
which fails to respond to RANKL.  Reflecting this fact, mice homozygous for the 75dup27 
variant had features of osteopetrosis in vivo which include metaphyseal widening and sclerosis 
of the tibia and femur and total absence of osteoclasts in histological sections. Furthermore, the 
bone marrow cavity was filled with mineralized cartilage which is confirmed by significantly 
higher BV/TV, Tb.N, Tb.Th and Trabecular area. Consistent with this, bone marrow cells from 
these mice failed to differentiate into osteoclasts in response to MCSF and RANKL 
stimulation, a phenotype that is similar to that of mice with targeted inactivation of RANK (15). 
In contrast, Tnfrsf11a75dup27/- mice appeared normal at a young adult age (4 month) but analysis 
by histomorphometry showed a trend for lower OC.N/BS compared to WT, nonetheless 
trabecular bone indices analyzed by micro CT showed no significant differences between 
heterozygous and WT mice. Additionally, the serum levels of bone turnover markers P1NP 
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and CTX-I were comparable to those observed in age-matched WT mice, however serum levels 
of RANKL were significantly reduced in heterozygous mice. 
 When heterozygous mice were analyzed at an older age (12 months), they exhibited higher 
BV/TV, Tb.N, and Tb.Th and there was an evidence of bone enlargement as evident from 
larger peripheral circumference in hind limbs of heterozygous mice compared to WT. 
However, the skull bones from these mice were normal with no significant differences to WT. 
 We also found that heterozygous mice developed focal osteolytic lesions in the lower limbs 
with increasing age, consistent with the phenotype observed in humans with this mutation. At 
the age of 12 months, most animals developed osteolytic lesions at the proximal tibia and distal 
femur close to the growth plate and the lesion severity was found to increase with age.  
 To identify the molecular mechanisms involved in the maintenance of the osteoclast activity, 
we evaluated a number of molecular targets from MAPK and NF-κB pathways, associated with 
osteoclastogenesis and osteoclast function. We found that cells cultured from mice 
heterozygous for the 75dup27 mutation showed a decreased IκB and p38 phosphorylation, 
compared to wild type controls. A decrease in the expression of the active form of IκB (pIκB) 
has been associated with reduced osteoclastogenesis (reviewed in (16)). In the same line, p38, a 
member of the MAPK family, plays a role in the differentiation of bone marrow cells into 
osteoclasts (17). Therefore, the reduction in osteoclastogenesis found in the Tnfrsf11a75dup27/- 
model could be caused by a decrease in IκB and p38 activation. We also detected an increase 
of ERK phosphorylation in the heterozygotes compared with WT. ERK is involved in a number 
of processes in osteoclasts, including survival, proliferation, cell polarity, and differentiation, 
among others (18). Increasing ERK phosphorylation could be associated to the increased 
osteoclast survival found in our model, since the increase in pERK was sustained for longer 
time and became significant at 30 min post RANKL activation.  Additionally, basal c-Fos 
expression was higher in osteoclast precursors of heterozygous animals which may also 
partially explain the increased survival of osteoclasts.   
Analysis of NF-κB activity during osteoclast differentiation in the Tnfrsf11a75dup27/- mice 
showed that RANKL-induced NF-κB activation was reduced in heterozygous animals 
compared to WT, consistent with  our western blot results and with previous in vitro studies (5). 
However, after withdrawal of RANKL, the NF-κB expression is sustained and increased 
compared with wild type controls. NF-κB is important for osteoclast function and survival 
(reviewed in (19)), and its continuous activation to trigger RANK pathway in absence of the 
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ligand could be associated with increased osteoclast survival, ultimately leading to the bone 
lesions reminiscent of Paget’s disease that were found in the Tnfrsf11a75dup27/- mice in vivo.   
Previous in vitro studies have reported a continuous activation of the RANK pathway caused 
by mutations in the signal peptide of RANK leading to a hyperactivity of the osteoclasts, but 
the mechanism involved was unclear (3). It has been demonstrated that the 75dup27 and other 
mutations in the signal peptide of RANK impair cleavage of the signal peptide and prevent the 
RANK protein migrating to the plasma membrane (20,21). Instead the mutant protein has been 
shown to accumulate in OSER-like structures in endoplasmic reticulum (22). The mechanism 
by which the abnormal protein stimulates osteoclast survival is unknown but a possibility 
would be by triggering the unfolded protein response (UPR) which is known to cause activation 
of NF-κB signaling (23). Furthermore, accumulation of unfolded proteins and/or a decreased 
capacity to degrade unfolded proteins with age (24), could contribute to increased penetrance of 
the Paget’s disease-like phenotype with age that we observed in Tnfrsf11a75dup27/- mice.  
In addition to clarifying the mechanisms of action by which these mutations cause osteolytic 
lesions, the present experiment has shown that when administered early in life, zoledronic acid 
can prevent the development of lesions at older age. While bisphosphonates have not been 
shown to reverse bone deformity, improve mobility or prevent deafness and tooth loss in 
patients with EoPDB (2), it should be noted that the treatment was administered at a late stage 
in the disease process. Our data suggest that if prophylactic therapy was given at an early stage, 
it may be possible to prevent or inhibit the progression of bone disease in this severe and 
disabling disorder.    
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Figure Legends 
Figure 1. X-ray images of mice with Tnfrsf11a 75dup27 mutation. Upper row: wild type 
(WT; 15 month female), Tnfrsf11a75dup27/- (15 month, female) and Tnfrsf11a75dup27/75dup27 (2.5 
month female) mice. lower row: X-ray amplification of the knee joint showing part of the 
femur, tibia and fibula. Arrows indicate bone lesions in heterozygote animals. Homozygote 
animals show metaphyseal widening and sclerosis of the tibia and femur characteristic of 
osteopetrosis. 
 
Figure 2. Analysis of bone phenotype in 4-month-old Tnfrsf11a75dup27/75dup27 mice. (A, D) 
Bone sections from female WT (A) and Tnfrsf11a75dup27/75dup27 (D) mice stained with Safranin 
O, to visualize cartilage matrix (red color), and Fast green as a counterstain. The marked section 
of the image is shown at higher magnification in the panel below.  (B, E) Representative 3D 
MicroCT images of tibia from WT (B) and Tnfrsf11a75dup27/75dup27 (E) mice. (C, F) Bone 
sections from WT (C) and Tnfrsf11a75dup27/75dup27 (F) mice stained with TRAcP, to visualize 
osteoclasts (indicated by arrows), and Aniline Blue as a counterstain. (G) MicroCT analysis of 
bone structure showing comparison of bone volume/tissue volume (BV/TV), trabecular 
thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N), trabecular area 
(T.Ar) and peripheral circumference (Per.Circ) between WT (n=6) and Tnfrsf11a75dup27/75dup27 
(HOM; n=6) mice. (H) Representative images of TRAcP stained osteoclast cultures from 
Tnfrsf11a75dup27/75dup27 compared to WT, after stimulation of bone marrow derived 
macrophages with MCSF and different concentrations of RANKL for 5 days. Results are 
representative of three independent biological replicates. 
 
Figure 3. Analysis of bone phenotype in 12-month-old Tnfrsf11a75dup27/- mice by MicroCT. 
(A) Representative 3D MicroCT images of distal femur from WT and Heterozygous mice 
(Het). (B) Comparison of cortical thickness (Cort.Th), peripheral circumference (Per.Circ), 
bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation 
(Tb.Sp) and trabecular number (Tb.N) between WT (n=6) and Het (n=7) female mice. (C) 
Representative 3D MicroCT images of the skull from WT and Het mice. (D) Comparison of 
skull bone width, height and length between WT (n=6) and Het (n=6) female mice. 
 
Figure 4. Bone lesions in Tnfrsf11a75dup27/- mice. (A) Representative 3D MicroCT images of 
proximal femur from female WT and Tnfrsf11a75dup27/- (Het) mice. The most common sites for 
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lesions were distal femur (indicated by arrows) and proximal tibia (not shown). (B) Box and 
whisker plot showing lesion score in 12-month and 15-month old female Het animals compared 
to WT; n indicates the number of animals per group. (C,E) Representative 3D MicroCT images 
of tibia from a 15-month old female WT (C) compared to Het (E) mouse showing the 
development of severe bone lesions (black arrows). The panels to the right represent a 
longitudinal and axial view, respectively, showing the lesions detected in the tibial cortex of 
Het mice (indicated by red arrows and oval markings). (D,F) Histological sections of the 
regions indicated by red oval markings from WT (D) and Het (F) mice. Bone sections were 
stained with TRAcP, to visualize osteoclasts, and Aniline Blue as a counterstain. The panel to 
the right represents a higher magnification image. Scale bars = 100µm unless stated otherwise. 
 
Figure 5. Osteoclast cultures from 4-month-old Tnfrsf11a75dup27/- . (A) Representative 
images of TRAcP stained osteoclast cultures from Tnfrsf11a75dup27/- (Het) compared to WT 
after stimulation with MCSF and different concentrations of RANKL. Scale bar = 100 µm (B) 
Quantification of the number of osteoclasts (OC) formed after RANKL stimulation in Het and 
WT mice. (C) Percentage of large osteoclast (> 5 nuclei) over total number of osteoclasts in 
Het and WT mice after RANKL stimulation. (D) Quantification of the percentage of osteoclast 
survival after RANKL withdrawal in Het and WT mice at the indicated time points. Results 
are representative of three independent biological replicates from female mice.  
 
Figure 6. Analysis of signaling pathways in 4-month-old Tnfrsf11a75dup27/- mice. (A) 
Western blot images of pERK; pIκB; and pp38 in primary osteoclast cultures from 
Tnfrsf11a75dup27/- (Het) compared to WT mice at the indicated time points of RANKL 
stimulation. (B) Band intensity analysis of pERK; pIκB; and pp38.  (C) Western blot images 
of cFos in primary osteoclast cultures from Het compared to WT mice after RANKL 
stimulation. The box plot to the right represents band intensity analysis of cFos. All western 
blot results are shown as a percentage of unstimulated WT (0 min) and were from 2-4 
independent biological replicates. (D) Luciferase assay for NF-κB activation during osteoclast 
differentiation from bone marrow derived cells upon stimulation with RANKL in WT 
compared to Het. (E) RANKL withdrawal; luciferase assay for NF-κB activation in osteoclasts 
and up to 48 hours post RANKL withdrawal. Results are representative of three independent 
biological replicates.  
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Figure 7. Serum levels of biochemical markers of bone turnover in 4-month-old RANK 
Tnfrsf11a75dup27/- mice. (A) Serum levels of Procollagen Type I N-terminal propeptide (P1NP); 
(B) carboxy-terminal telopeptide cross-links (CTX-I); and (C) RANKL in WT (n=8) compared 
to Tnfrsf11a75dup27/- (Het; n=8) female mice.  
 
Figure 8. Effect of Zoledronic acid treatment on the development of bone lesions in RANK 
Tnfrsf11a75dup27/- mice. Bone lesions in 15-month-old Tnfrsf11a75dup27/- female mice treated 
with zoledronic acid (n=8) or PBS (n=8). (A) Box and whisker plot showing lesion score. (B) 
Representative 3D MicroCT images of tibia and femur from heterozygous animals treated with 
PBS (Het-PBS) or zoledronic acid (Het-Zol). Arrows indicate observed bone lesions. No 
lesions were observed in the zoledronic acid group. 
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